April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Differential systemic gene expression profile in patients with diabetic macular edema: responders versus non-responders
Author Affiliations & Notes
  • Shwetha Mangalesh
    Retina, Narayana Nethralaya, Bangalore, India
  • Supriya Dabir
    Retina, Narayana Nethralaya, Bangalore, India
  • Debashish Das
    Stem Cell Biology, Narayana Nethralaya, Bangalore, India
  • Jeyabalan Nallathambi
    Genetic Research, Narayana Nethralaya, Bangalore, India
  • Naresh Yadav
    Retina, Narayana Nethralaya, Bangalore, India
  • Rohit Shetty
    Refractive, Narayana Nethralaya, Bangalore, India
  • Footnotes
    Commercial Relationships Shwetha Mangalesh, None; Supriya Dabir, None; Debashish Das, None; Jeyabalan Nallathambi, None; Naresh Yadav, None; Rohit Shetty, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1745. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shwetha Mangalesh, Supriya Dabir, Debashish Das, Jeyabalan Nallathambi, Naresh Yadav, Rohit Shetty; Differential systemic gene expression profile in patients with diabetic macular edema: responders versus non-responders. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1745.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To identify signaling pathways involved in the development of diabetic macular edema and assess the differential systemic gene expression profile based on response to treatment.

Methods: A pilot, case control, prospective, observational series where DME patients were treated with bevacizumab and sub classified as treatment naïve, treatment responders and treatment non-responders. RNA extraction followed by labelling, amplification and hybridisation was done and microarray data analysed. Genes were classified based on functional category and pathways.

Results: The total number of genes upregulated among all three experimental groups were 5 whereas 105 genes were downregulated. There were no common genes upregulated between the responders and non-responders. There was only 1 gene upregulated between the diabetic and diabetic responders post treatment. There were 19 genes upregulated and 8 genes downregulated in the inflammatory pathway in group 2 vs group 1. There were no down regulated genes detected in vascular angiogenesis and transcription group.There were identical numbers of genes up and down regulated in the inflammatory pathway. Seventeen genes were upreguated and 11 genes downregulated in receptor activity, that remained the predominant group in the group classification.

Conclusions: This study provides an insight into the probable signaling mechanisms for disease pathogenesis as well as progression. This eventually would aid in developing or improvising existing treatment modules with a rational approach towards personalized medicine, in future addressing the differential responses to treatment.This will herald the era of pharmacogenomics for titrating individualized treatment.

Keywords: 499 diabetic retinopathy • 535 gene microarray • 688 retina  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.